Real-World Comparative Survival Outcomes of First-Line Serplulimab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Single-Center Retrospective Cohort Study
Background Extensive-stage small-cell lung cancer (ES-SCLC) remains an aggressive malignancy with poor survival despite platinum-etoposide chemotherapy. Although serplulimab plus chemotherapy has demonstrated a survival benefit in randomized trials, comparative real-world evidence remains limited. We therefore evaluate...